Yale Cancer Center Experts to Present Latest Findings at American Society of Hematology’s Annual Meeting

Yale Cancer Center (YCC) researchers at Yale School of Medicine will present the latest in blood cancer and blood disorder research at the 2025 American Society of Hematology Annual Meeting from December 6 to 9 in Orlando, Florida.

The ASH Annual Meeting features hundreds of in person and virtual presentations highlighting cutting-edge findings and techniques in hematology. YCC experts will present new findings in key areas from vaccine effectiveness to new biomarkers and therapies for blood diseases.

YCC presentation highlights will include:

Friday, December 5

• Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies

Speaker: Amer Zeidan, MBBS

• Making the Most of Mentorship

Speaker: Alfred Lee, MD, PhD

• Challenges with PROs in Acute SCD Pain Clinical Trials: Why We Need Surrogate Biomarkers

Presenter: Nitya Bakshi, MBBS, MS

Saturday, December 6

• Menstruating individuals: Evidence-based ferritin thresholds

Speaker: Layla Van Doren, MD

• Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Speaker: Amer Zeidan

• MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy

Speaker: Prateek Bhardwaj

Sunday, December 7

• The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Presenter: Jan Bewersdorf, MD

• Hematopoiesis in the Golden Years: Aging, Epigenetic Landscapes, and Clonal Destiny

Speaker: Stephanie Halene, MD

• Early TCR diversity and recipient stem-cell persistence predict relapse and reveal therapeutic targets after allogeneic transplantation

Speaker: Nurefsan Sariipek

Monday, December 8

• Outcomes Research in Hematology

Speaker: Scott Huntington, MD

• Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis

Presenter: Konan Beke

• Influenza vaccine coverage, effectiveness, and disease burden among pediatric sickle cell patients in Connecticut from 2021-2024: A test-negative case-control study

Speaker: Inci Yildirim, MD, PhD

About Yale Cancer Center: Yale Cancer Center, a National Cancer Institute (NCI) designated comprehensive cancer center since 1974, is recognized for its groundbreaking research and innovative cancer treatment approaches. As the only NCI-designated comprehensive cancer center in Connecticut, YCC is dedicated to delivering excellence in patient care, research, and education. Through its partnership with Smilow Cancer Hospital, YCC continues to lead the way in advancing cancer research and offering hope to patients worldwide.

For a complete list of Yale Cancer Center presentations at ASH 2025, please see the attached document.